Jaime Gomez, MD
Cardiovascular Disease · Brownsville, TXNPI 1376595256
Payments from drug & device makers
Across 390 payments — averaging $171.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$24K
- Siemens Medical Solutions USA, Inc.$20K
- Baxter Healthcare$4K
- Biotronik Inc.$4K
- Pfizer$3K
- Boston Scientific$2K
- plus $10K from 34 others
What the payments were for
- Consulting fees$9,00013%
- Speaking & faculty fees$22,45034%
- Travel & lodging$13,20420%
- Food & beverage$17,25726%
- Education$100%
- Other$5,0908%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 111 | $23,616 |
| Siemens Medical Solutions USA, Inc. | 38 | $20,128 |
| Baxter Healthcare | 1 | $4,222 |
| Biotronik Inc. | 50 | $4,135 |
| Pfizer | 11 | $2,651 |
| Boston Scientific | 16 | $2,237 |
| Abbott | 45 | $1,840 |
| Silk Road Medical, Inc. | 18 | $1,147 |
| Abiomed | 10 | $920 |
| Merit Medical Systems Inc | 1 | $868 |
| Cvrx, Inc. | 3 | $755 |
| Medtronic(2 entities) | 8 | $537 |
| Heartflow, Inc. | 5 | $475 |
| Chiesi USA, Inc. | 21 | $400 |
| Cardiovascular Systems Inc. | 5 | $390 |
| Terumo Medical Corporation | 5 | $285 |
| Edwards Lifesciences | 2 | $283 |
| Bolton Medical Inc | 2 | $264 |
| Corindus Inc. | 1 | $216 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $166 |
| Shockwave Medical, Inc | 2 | $158 |
| Boehringer Ingelheim | 4 | $150 |
| Bard Peripheral Vascular, Inc. | 1 | $147 |
| W. L. Gore & Associates, Inc. | 1 | $146 |
| Organogenesis Inc. | 2 | $126 |
| GE HealthCare | 1 | $122 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $106 |
| Amgen | 6 | $102 |
| Reflow Medical Inc | 1 | $91 |
| Johnson & Johnson | 4 | $71 |
| Inspiremd Ltd | 1 | $63 |
| Acist Medical Systems, Inc. | 1 | $41 |
| Novo Nordisk | 1 | $24 |
| Novartis | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Bayer | 1 | $21 |
| Teleflex LLC | 1 | $18 |
| AstraZeneca | 1 | $15 |
| Merck | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$24,329
- CorPath GRX$1,875
- ROTABLATOR$1,496
- BioMonitor$998
- Barostim Neo System$721
- Solia$705
- Acticor$604
- Rivacor$604
- Edora$604
- ENROUTE Transcarotid Neuroprotection System$566
- ENROUTE Transcarotid Stent$416
- Edora 8 DR-T$408
- Impella$392
- Acticor 7 VR-T DX$372
- FFRct$337
- Relay Grafts$264
- CorPath Imaging System$241
- Plexa ProMRI$230
- CAMZYOS$228
- Diamondback Coronary$223
How this compares
$67,010 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 179 | $225,558 |
| EliquisApixaban | 177 | $218,797 |
| XareltoRivaroxaban | 51 | $60,423 |
| FarxigaDapagliflozin Propanediol | 29 | $31,521 |
| VerquvoVericiguat | 22 | $25,803 |
| Repatha SureclickEvolocumab | 21 | $25,167 |
| MultaqDronedarone Hcl | 23 | $23,576 |
| BrilintaTicagrelor | 32 | $18,034 |
| JardianceEmpagliflozin | 13 | $14,526 |
| Ranolazine ErRanolazine | 71 | $7,090 |
| Metoprolol Succinate | 159 | $2,732 |
| Clonidine | 13 | $2,185 |
| Rosuvastatin Calcium | 172 | $1,988 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 149 | $1,826 |
| ClopidogrelClopidogrel Bisulfate | 152 | $1,699 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $24 | $225,558179 claims |
| PfizerEliquis | $2,651 | $218,797177 claims |
| Johnson & JohnsonXarelto | $71 | $60,42351 claims |
| AstraZenecaFarxiga, Brilinta | $15 | $49,55561 claims |
| MerckVerquvo | $14 | $25,80322 claims |
| Boehringer IngelheimJardiance | $150 | $14,52613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Brownsville
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.